RATIONALE: Experimental evidence suggests that the differential behavioral effects of benzodiazepines depend on their relative actions at γ-aminobutyric acid type A (GABA(A)) receptors that contain either an α1, α2, α3, or α5 subunit. OBJECTIVES: The present study was aimed at understanding the role of α3 subunit-containing GABA(A) (α3GABA(A)) receptors by examining the behavioral pharmacology of TP003 (4,2'-difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridine-3-yl]biphenyl-2-carbonitrile), which shows functional selectivity for α3GABA(A) receptors. METHODS: First, a conflict procedure was used to assess the anxiolytic-like effects of TP003 and a representative clinically available benzodiazepine. TP003 was also administered before daily periods of sucrose pellet availability to evaluate potential hyperphagic effects. In separate experiments, observable behavioral effects were used to assess the motor and sedative effects of TP003. RESULTS: Administration of TP003 produced robust anti-conflict effects without the rate-decreasing effects that were observed with the representative benzodiazepine. Unlike the reported effects of benzodiazepines, TP003 did not enhance palatable food consumption. However, increases in observable sleep-associated posture were induced by TP003, as were decreases in some species-typical behaviors (vocalization, locomotion, and environment-directed behaviors). When evaluated for its ability to induce a procumbent posture, TP003 failed to produce an effect. CONCLUSIONS: Based on conflict and observation tests in monkeys, our results suggest that TP003 may have anxiolytic properties but lack ataxic, hyperphagic, and pronounced sedative effects characteristic of classical benzodiazepines. TP003 did induce myorelaxant-like effects and had relatively mild sedative effects. Collectively, these results suggest that α3GABA(A) receptors play an important role in the anxiolytic-like and motor effects of benzodiazepine-type drugs.
RATIONALE: Experimental evidence suggests that the differential behavioral effects of benzodiazepines depend on their relative actions at γ-aminobutyric acid type A (GABA(A)) receptors that contain either an α1, α2, α3, or α5 subunit. OBJECTIVES: The present study was aimed at understanding the role of α3 subunit-containing GABA(A) (α3GABA(A)) receptors by examining the behavioral pharmacology of TP003 (4,2'-difluoro-5'-[8-fluoro-7-(1-hydroxy-1-methylethyl)imidazo[1,2-a]pyridine-3-yl]biphenyl-2-carbonitrile), which shows functional selectivity for α3GABA(A) receptors. METHODS: First, a conflict procedure was used to assess the anxiolytic-like effects of TP003 and a representative clinically available benzodiazepine. TP003 was also administered before daily periods of sucrose pellet availability to evaluate potential hyperphagic effects. In separate experiments, observable behavioral effects were used to assess the motor and sedative effects of TP003. RESULTS: Administration of TP003 produced robust anti-conflict effects without the rate-decreasing effects that were observed with the representative benzodiazepine. Unlike the reported effects of benzodiazepines, TP003 did not enhance palatable food consumption. However, increases in observable sleep-associated posture were induced by TP003, as were decreases in some species-typical behaviors (vocalization, locomotion, and environment-directed behaviors). When evaluated for its ability to induce a procumbent posture, TP003 failed to produce an effect. CONCLUSIONS: Based on conflict and observation tests in monkeys, our results suggest that TP003 may have anxiolytic properties but lack ataxic, hyperphagic, and pronounced sedative effects characteristic of classical benzodiazepines. TP003 did induce myorelaxant-like effects and had relatively mild sedative effects. Collectively, these results suggest that α3GABA(A) receptors play an important role in the anxiolytic-like and motor effects of benzodiazepine-type drugs.
Authors: K Löw; F Crestani; R Keist; D Benke; I Brünig; J A Benson; J M Fritschy; T Rülicke; H Bluethmann; H Möhler; U Rudolph Journal: Science Date: 2000-10-06 Impact factor: 47.728
Authors: Neil Collinson; Frederick M Kuenzi; Wolfgang Jarolimek; Karen A Maubach; Rosa Cothliff; Cyrille Sur; Alison Smith; Franklin M Otu; Owain Howell; John R Atack; Ruth M McKernan; Guy R Seabrook; Gerry R Dawson; Paul J Whiting; Thomas W Rosahl Journal: J Neurosci Date: 2002-07-01 Impact factor: 6.167
Authors: Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett Journal: Neuropharmacology Date: 2010-08-18 Impact factor: 5.250
Authors: Donna M Platt; James K Rowlett; Roger D Spealman; James Cook; Chunrong Ma Journal: Psychopharmacology (Berl) Date: 2002-09-04 Impact factor: 4.530
Authors: U Rudolph; F Crestani; D Benke; I Brünig; J A Benson; J M Fritschy; J R Martin; H Bluethmann; H Möhler Journal: Nature Date: 1999-10-21 Impact factor: 49.962
Authors: R M McKernan; T W Rosahl; D S Reynolds; C Sur; K A Wafford; J R Atack; S Farrar; J Myers; G Cook; P Ferris; L Garrett; L Bristow; G Marshall; A Macaulay; N Brown; O Howell; K W Moore; R W Carling; L J Street; J L Castro; C I Ragan; G R Dawson; P J Whiting Journal: Nat Neurosci Date: 2000-06 Impact factor: 24.884
Authors: F Crestani; R Keist; J-M Fritschy; D Benke; K Vogt; L Prut; H Blüthmann; H Möhler; U Rudolph Journal: Proc Natl Acad Sci U S A Date: 2002-06-25 Impact factor: 11.205
Authors: Bradford D Fischer; Raymond J Schlitt; Bryan Z Hamade; Sabah Rehman; Margot Ernst; Michael M Poe; Guanguan Li; Revathi Kodali; Leggy A Arnold; James M Cook Journal: Brain Res Bull Date: 2017-03-04 Impact factor: 4.077
Authors: Lais F Berro; Daniela Rüedi-Bettschen; Jemma E Cook; Lalit K Golani; Guanguan Li; Rajwana Jahan; Farjana Rashid; James M Cook; James K Rowlett; Donna M Platt Journal: Alcohol Clin Exp Res Date: 2019-04-08 Impact factor: 3.455
Authors: Angela N Duke; Zhiqiang Meng; Donna M Platt; John R Atack; Gerard R Dawson; David S Reynolds; V V N Phani Babu Tiruveedhula; Guanguan Li; Michael Rajesh Stephen; Werner Sieghart; James M Cook; James K Rowlett Journal: J Pharmacol Exp Ther Date: 2018-05-02 Impact factor: 4.030
Authors: Nina M Shinday; Eileen K Sawyer; Bradford D Fischer; Donna M Platt; Stephanie C Licata; John R Atack; Gerard R Dawson; David S Reynolds; James K Rowlett Journal: Neuropsychopharmacology Date: 2012-12-27 Impact factor: 7.853
Authors: Zhiqiang Meng; Lais F Berro; Eileen K Sawyer; Daniela Rüedi-Bettschen; Jemma E Cook; Guanguan Li; Donna M Platt; James M Cook; James K Rowlett Journal: J Psychopharmacol Date: 2019-10-31 Impact factor: 4.153
Authors: Raffaella Geracitano; David Fischer; Yu Kasugai; Francesco Ferraguti; Marco Capogna Journal: Front Neural Circuits Date: 2012-05-31 Impact factor: 3.492
Authors: Mohammad A Rahman; Thomas M Keck; Michael M Poe; Dishary Sharmin; James M Cook; Bradford D Fischer Journal: Psychopharmacology (Berl) Date: 2021-02-13 Impact factor: 4.415